{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:08:36Z","timestamp":1788883716232,"version":"build-2803163510"},"reference-count":48,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Iron overload is a significant cause of transfusion-related morbidity and mortality. Deferiprone (DFP) is an established oral iron chelator approved for the treatment of transfusional iron overload in patients with thalassemia, sickle cell disease (SCD), or other anemias. Although DFP was initially approved as a thrice daily formulation, a twice daily formulation was developed to improve patients\u2019 treatment adherence. Here, we assess the safety of DFP twice daily in patients with thalassemia, SCD, or other anemias in real-world clinical practice in the United States. Data for patients referred for DFP twice daily between 1 July 2020 and 31 August 2023 were obtained from the Ferriprox Total Care Registry. The frequencies of adverse events (AEs), serious AEs (SAEs), AEs of special interest, and fatal outcomes were assessed. Of the 425 patients referred to the registry, 348 received \u22651 DFP shipment, and was designated the safety analysis group. The primary diagnosis was a thalassemia syndrome in 129, SCD in 189, and other anemia in 30 patients. Mean (standard deviation) DFP exposure was 343.0 (281.9) days. In total, 1021 AEs and 369 SAEs were reported. As seen with the thrice daily formulation, the most common AEs associated with DFP twice daily were predominantly gastrointestinal or related to underlying disease. Cases of neutropenia and agranulocytosis were rare, reported in 1.7% and 0.6% of patients, respectively, and all cases recovered. None of the 26 fatal outcomes reported were assessed as related to DFP treatment. DFP twice daily was well tolerated in real-world clinical practice, and its safety profile was consistent with DFP thrice daily. No new safety concerns were observed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019368","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:56:47Z","timestamp":1780606607000},"page":"5886-5898","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Real-world safety profile of twice a day deferiprone in patients with thalassemia, sickle cell disease, or other anemias"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7640-1244","authenticated-orcid":false,"given":"Sujit","family":"Sheth","sequence":"first","affiliation":[{"name":"1Division of Pediatric Hematology\/Oncology, Weill Cornell Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0082-3536","authenticated-orcid":false,"given":"Ashutosh","family":"Lal","sequence":"additional","affiliation":[{"name":"2Division of Pediatric Hematology, University of California San Francisco School of Medicine, University of California San Francisco Benioff Children\u2019s Hospital, Oakland, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8147-3624","authenticated-orcid":false,"given":"Abena","family":"Appiah-Kubi","sequence":"additional","affiliation":[{"name":"3Department of Pediatric Hematology\/Oncology & Cellular Therapy, Northwell Health, New York, NY"},{"name":"4Division of Hematology\/Oncology and Cellular Therapy, Cohen Children\u2019s Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1483-1545","authenticated-orcid":false,"given":"Scott A.","family":"Peslak","sequence":"additional","affiliation":[{"name":"5Division of Hematology\/Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4347-9988","authenticated-orcid":false,"given":"Noemi","family":"Toiber Temin","sequence":"additional","affiliation":[{"name":"6Chiesi Canada Corp, Woodbridge, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1767-6460","authenticated-orcid":false,"given":"Mengru Amanda","family":"Chen","sequence":"additional","affiliation":[{"name":"7Chiesi Limited, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9878-6029","authenticated-orcid":false,"given":"Thomas","family":"Coates","sequence":"additional","affiliation":[{"name":"8Cancer and Blood Disease Institute, Children\u2019s Hospital Los Angeles, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"issue":"5","key":"2026090811320043600_bib1","doi-asserted-by":"crossref","first-page":"103764","DOI":"10.1016\/j.transci.2023.103764","article-title":"Global burden of transfusion in sickle cell disease","volume":"62","author":"Inusa","year":"2023","journal-title":"Transfus Apher Sci"},{"issue":"12","key":"2026090811320043600_bib2","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1111\/trf.14875","article-title":"Transfusion practices and complications in thalassemia","volume":"58","author":"Lal","year":"2018","journal-title":"Transfusion"},{"key":"2026090811320043600_bib3","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/9781119719809.ch51","volume-title":"Rossi's Principles of Transfusion Medicine","author":"Sheth","year":"2022"},{"issue":"1","key":"2026090811320043600_bib4","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1080\/13696998.2023.2235928","article-title":"Economic and clinical burden of managing transfusion-dependent \u03b2-thalassemia in the United States","volume":"26","author":"Udeze","year":"2023","journal-title":"J Med Econ"},{"issue":"12","key":"2026090811320043600_bib5","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.3390\/ijms18122778","article-title":"Iron overload and chelation therapy in non-transfusion dependent thalassemia","volume":"18","author":"Bou-Fakhredin","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"21","key":"2026090811320043600_bib6","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood.V122.21.1005.1005","article-title":"Transfusional iron overload in an adult sickle cell disease population: epidemiology, prevalence, and management","volume":"122","author":"Son","year":"2013","journal-title":"Blood"},{"key":"2026090811320043600_bib7","author":"Baddam","year":"; 2025"},{"issue":"11","key":"2026090811320043600_bib8","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.20685","article-title":"Circumstances of death in adult sickle cell disease patients","volume":"81","author":"Darbari","year":"2006","journal-title":"Am J Hematol"},{"key":"2026090811320043600_bib9","unstructured":"Ferriprox USPI\n          . US Food and Drug Administration. Accessed 30 June 2025. https:\/\/resources.chiesiusa.com\/Ferriprox\/FERRIPROX_PI_US.pdf."},{"issue":"21","key":"2026090811320043600_bib10","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.1182\/bloodadvances.2023012316","article-title":"Rates of severe neutropenia and infection risk in patients treated with deferiprone: 28 years of data","volume":"8","author":"Badawy","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"2026090811320043600_bib11","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1006\/bcmd.2002.0510","article-title":"Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial","volume":"28","author":"Maggio","year":"2002","journal-title":"Blood Cells Mol Dis"},{"issue":"4","key":"2026090811320043600_bib12","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/bloodadvances.2021004938","article-title":"Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study","volume":"6","author":"Kwiatkowski","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"2026090811320043600_bib13","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/S2352-3026(20)30100-9","article-title":"Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial","volume":"7","author":"Maggio","year":"2020","journal-title":"Lancet Haematol"},{"issue":"10","key":"2026090811320043600_bib14","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/ajh.24479","article-title":"Deferiprone-induced agranulocytosis: 20 years of clinical observations","volume":"91","author":"Tricta","year":"2016","journal-title":"Am J Hematol"},{"issue":"6","key":"2026090811320043600_bib15","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/ajh.27276","article-title":"Real-world evidence: long-term safety of deferiprone in a large cohort of patients with sickle cell disease enrolled in a registry for up to 10 years","volume":"99","author":"Kwiatkowski","year":"2024","journal-title":"Am J Hematol"},{"issue":"5","key":"2026090811320043600_bib16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s12185-011-0927-3","article-title":"Challenges of adherence and persistence with iron chelation therapy","volume":"94","author":"Porter","year":"2011","journal-title":"Int J Hematol"},{"issue":"1","key":"2026090811320043600_bib17","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1111\/bjh.17999","article-title":"The safety and acceptability of twice-daily deferiprone for transfusional iron overload: a multicentre, open-label, phase 2 study","volume":"197","author":"Badawy","year":"2022","journal-title":"Br J Haematol"},{"issue":"1","key":"2026090811320043600_bib18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12955-023-02221-y","article-title":"The impact of chelation compliance in health outcome and health related quality of life in thalassaemia patients: a systematic review","volume":"22","author":"Lee","year":"2024","journal-title":"Health Qual Life Outcomes"},{"issue":"10","key":"2026090811320043600_bib19","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1111\/j.1537-2995.2007.01416.x","article-title":"Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review","volume":"47","author":"Delea","year":"2007","journal-title":"Transfusion"},{"issue":"1","key":"2026090811320043600_bib20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/pds.3891","article-title":"Guidelines for good pharmacoepidemiology practice (GPP)","volume":"25","author":"Public Policy Committee International Society of Pharmacoepidemiology","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026090811320043600_bib21","unstructured":"The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP)\n          . Guide on Methodological Standards in Pharmacoepidemiology (Revision 11). EMA\/95098\/2010. Accessed 2 July 2026. https:\/\/encepp.europa.eu\/encepp-toolkit\/methodological-guide_en#encepp-guide-on-methodological-standards-in-pharmacoepidemiology."},{"key":"2026090811320043600_bib22","author":"European Medicines Agency","year":"2016"},{"key":"2026090811320043600_bib23","unstructured":"Medical Dictionary for Regulatory Activities\n          . International Council for Harmonisation of technical requirements for Pharmaceuticals for Human use [ICH]. Accessed 23 October 2025. https:\/\/www.meddra.org\/."},{"issue":"suppl 1","key":"2026090811320043600_bib24","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2025-2667","article-title":"Iron overload is prevalent, likely underdiagnosed and undertreated in sickle cell disease: a real-world report from the ASH research collaborative","volume":"146","author":"Wilson","year":"2025","journal-title":"Blood"},{"issue":"5","key":"2026090811320043600_bib25","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/bjh.14575","article-title":"How we manage iron overload in sickle cell patients","volume":"177","author":"Coates","year":"2017","journal-title":"Br J Haematol"},{"issue":"1 suppl 1","key":"2026090811320043600_bib26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0037-1963(01)90058-7","article-title":"Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease","volume":"38","author":"Ballas","year":"2001","journal-title":"Semin Hematol"},{"issue":"4","key":"2026090811320043600_bib27","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/bloodadvances.2021006778","article-title":"Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years","volume":"7","author":"Elalfy","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"2026090811320043600_bib28","doi-asserted-by":"crossref","first-page":"e0214355","DOI":"10.1371\/journal.pone.0214355","article-title":"Sickle cell disease complications: prevalence and resource utilization","volume":"14","author":"Shah","year":"2019","journal-title":"PLoS One"},{"issue":"11","key":"2026090811320043600_bib29","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3324\/haematol.2011.047365","article-title":"Frequency of pain crises in sickle cell anemia and its relationship with the sympatho-vagal balance, blood viscosity and inflammation","volume":"96","author":"Nebor","year":"2011","journal-title":"Haematologica"},{"key":"2026090811320043600_bib30","doi-asserted-by":"crossref","first-page":"100495","DOI":"10.1016\/j.lansea.2024.100495","article-title":"Deferoxamine, deferasirox, and deferiprone triple iron chelator combination therapy for transfusion-dependent \u03b2-thalassaemia with very high iron overload: a randomised clinical trial","volume":"30","author":"Premawardhena","year":"2024","journal-title":"Lancet Reg Health Southeast Asia"},{"issue":"4","key":"2026090811320043600_bib31","doi-asserted-by":"crossref","first-page":"e872","DOI":"10.1097\/HS9.0000000000000872","article-title":"The European guidelines on diagnosis and management of neutropenia in adults and children: a consensus between the European Hematology Association and the EuNet-INNOCHRON COST Action","volume":"7","author":"Fioredda","year":"2023","journal-title":"Hemasphere"},{"issue":"6","key":"2026090811320043600_bib32","doi-asserted-by":"crossref","first-page":"e30945","DOI":"10.1002\/pbc.30945","article-title":"Prevalence of Duffy null and its impact on hydroxyurea in young children with sickle cell disease in the United States","volume":"71","author":"Oladipupo","year":"2024","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2026090811320043600_bib33","doi-asserted-by":"crossref","first-page":"e31693","DOI":"10.1002\/pbc.31693","article-title":"Prevalence of Duffy null and its impact on hydroxyurea dosing in children with sickle cell disease","volume":"72","author":"Menell","year":"2025","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2026090811320043600_bib34","doi-asserted-by":"crossref","first-page":"e2024067341","DOI":"10.1542\/peds.2024-067341","article-title":"Trends in sickle cell disease mortality: 1979-2020","volume":"154","author":"Karkoska","year":"2024","journal-title":"Pediatrics"},{"issue":"3","key":"2026090811320043600_bib35","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/pbc.22826","article-title":"Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent \u03b2-thalassemia","volume":"56","author":"Chang","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"19","key":"2026090811320043600_bib36","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2009-05-222729","article-title":"Deferasirox pharmacokinetics in patients with adequate versus inadequate response","volume":"114","author":"Chirnomas","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2026090811320043600_bib37","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.clinthera.2015.05.506","article-title":"Simultaneous determination of plasma deferasirox and deferasirox-iron complex using an HPLC-UV system and pharmacokinetics of deferasirox in patients with \u03b2-thalassemia major: once-daily versus twice-daily administration","volume":"37","author":"Lu","year":"2015","journal-title":"Clin Ther"},{"issue":"4","key":"2026090811320043600_bib38","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1177\/08971900211038301","article-title":"Efficacy and tolerability of twice-daily dosing schedule of deferasirox in transfusion-dependent paediatric beta-thalassaemia patients: a randomized controlled study","volume":"36","author":"Panachiyil","year":"2023","journal-title":"J Pharm Pract"},{"issue":"21","key":"2026090811320043600_bib39","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood.V124.21.2675.2675","article-title":"Twice daily use of deferasirox is more effective in decreasing serum ferritin","volume":"124","author":"Gumruk","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2026090811320043600_bib40","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.2023022502","article-title":"Management of iron overload: lessons from transfusion-dependent hemoglobinopathies","volume":"145","author":"Coates","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2026090811320043600_bib41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/nyas.15052","article-title":"Combination chelation therapy","volume":"1529","author":"Aydinok","year":"2023","journal-title":"Ann NY Acad Sci"},{"issue":"21","key":"2026090811320043600_bib42","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1182\/blood.V122.21.559.559","article-title":"Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with \u03b2-thalassemia major","volume":"122","author":"Elalfy","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2026090811320043600_bib43","doi-asserted-by":"crossref","first-page":"912","DOI":"10.4081\/cp.2017.912","article-title":"Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusion-dependent \u03b2-thalassemia major","volume":"7","author":"Karami","year":"2017","journal-title":"Clin Pract"},{"issue":"10","key":"2026090811320043600_bib44","doi-asserted-by":"crossref","first-page":"E338","DOI":"10.1002\/ajh.25222","article-title":"Daily alternating deferasirox and deferiprone therapy successfully controls iron accumulation in untreatable transfusion-dependent thalassemia patients","volume":"93","author":"Pinto","year":"2018","journal-title":"Am J Hematol"},{"issue":"11","key":"2026090811320043600_bib45","first-page":"e48276","article-title":"Efficacy and safety of combined deferiprone and deferasirox in iron-overloaded patients: a systematic review","volume":"15","author":"Salem","year":"2023","journal-title":"Cureus"},{"issue":"5","key":"2026090811320043600_bib46","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/ejh.12507","article-title":"Efficacy and safety of a novel combination of two oral chelators deferasirox\/deferiprone over deferoxamine\/deferiprone in severely iron overloaded young beta thalassemia major patients","volume":"95","author":"Elalfy","year":"2015","journal-title":"Eur J Haematol"},{"key":"2026090811320043600_bib47","unstructured":"Ferriprox SmPC\n          . European Medicines Agency. Accessed 30 November 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ferriprox-epar-product-information_en.pdf."},{"key":"2026090811320043600_bib48","author":"Taher","year":"2025","edition":"5th ed"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/5886\/2541735\/blooda_adv-2025-019368-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/5886\/2541735\/blooda_adv-2025-019368-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:32:11Z","timestamp":1788881531000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/17\/5886\/568878\/Real-world-safety-profile-of-twice-a-day"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":48,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026,9,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019368","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,8]]},"published":{"date-parts":[[2026,8,28]]}}}